Literature DB >> 17178769

Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception.

J Cory Kalvass1, Emily R Olson, Gary M Pollack.   

Abstract

Previous studies have indicated that P-glycoprotein (P-gp) attenuates the central nervous system penetration and central activity of some opioids. The impact of P-gp-mediated efflux on the disposition and efficacy of the synthetic opioid alfentanil currently is unknown. In this study, P-gp-competent [mdr1a(+/+)] and P-gp-deficient [mdr1a(-/-)] mice were used to investigate the impact of P-gp-mediated efflux on the systemic pharmacokinetics, brain disposition, and central activity of alfentanil. Equipotent doses of alfentanil were administered to mdr1a(+/+) and mdr1a(-/-) mice (0.2 and 0.067 mg/kg, respectively), and the time course of brain and serum concentrations as well as antinociception were determined. A pharmacokinetic-pharmacodynamic (PK-PD) model was fit to the data and used to assess the impact of P-gp on parameters associated with alfentanil disposition and action. The mdr1a(+/+) mice were less sensitive to alfentanil than mdr1a(-/-) mice, requiring a 3-fold higher dose to produce similar antinociception. PK-PD modeling revealed no differences in alfentanil systemic pharmacokinetics between P-gp expressers and nonexpressers. However, the steady-state brain-to-serum concentration ratio (K(p,brain,ss)) was approximately 3-fold lower in mdr1a(+/+) mice compared with mdr1a(-/-) mice (0.19 +/- 0.01 versus 0.54 +/- 0.04, respectively). Consistent with the approximately 3-fold lower K(p,brain,ss), the antinociception versus serum concentration relationship in mdr1a(+/+) mice was shifted approximately 3-fold rightward compared with mdr1a(-/-) mice. However, there was no difference in the antinociception versus brain concentration relationship, or in the brain tissue EC(50) (11 +/- 1.8 versus 9.2 +/- 1.7 ng/g), between mdr1a(+/+) and mdr1a(-/-) mice. These results indicate that alfentanil is an in vivo P-gp substrate and are consistent with the hypothesis that P-gp-mediated efflux attenuates antinociception by reducing alfentanil K(p,brain,ss).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17178769     DOI: 10.1124/dmd.106.011445

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  11 in total

Review 1.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

2.  Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.

Authors:  Tuukka Saarikoski; Teijo I Saari; Nora M Hagelberg; Janne T Backman; Pertti J Neuvonen; Mika Scheinin; Klaus T Olkkola; Kari Laine
Journal:  Eur J Clin Pharmacol       Date:  2015-01-06       Impact factor: 2.953

3.  Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.

Authors:  E D Kharasch; A Francis; A London; K Frey; T Kim; J Blood
Journal:  Clin Pharmacol Ther       Date:  2011-05-11       Impact factor: 6.875

4.  P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception.

Authors:  Sarah M Brown; Scott D Campbell; Amanda Crafford; Karen J Regina; Michael J Holtzman; Evan D Kharasch
Journal:  J Pharmacol Exp Ther       Date:  2012-06-27       Impact factor: 4.030

Review 5.  Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance.

Authors:  Susan L Mercer; Andrew Coop
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

6.  Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model.

Authors:  Louise Karlsson; Christoph Hiemke; Björn Carlsson; Martin Josefsson; Johan Ahlner; Finn Bengtsson; Ulrich Schmitt; Fredrik C Kugelberg
Journal:  Psychopharmacology (Berl)       Date:  2010-12-30       Impact factor: 4.530

7.  Rifampicin markedly decreases the exposure to oral and intravenous tramadol.

Authors:  Tuukka Saarikoski; Teijo I Saari; Nora M Hagelberg; Mikko Neuvonen; Pertti J Neuvonen; Mika Scheinin; Klaus T Olkkola; Kari Laine
Journal:  Eur J Clin Pharmacol       Date:  2012-12-15       Impact factor: 2.953

8.  Assessment of blood-brain barrier permeability using the in situ mouse brain perfusion technique.

Authors:  Rong Zhao; J Cory Kalvass; Gary M Pollack
Journal:  Pharm Res       Date:  2009-04-22       Impact factor: 4.200

9.  The role of multidrug resistance-associated protein in the blood-brain barrier and opioid analgesia.

Authors:  Wendy Su; Gavril W Pasternak
Journal:  Synapse       Date:  2013-05-02       Impact factor: 2.562

10.  Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.

Authors:  Mari Fihlman; Tuija Hemmilä; Nora M Hagelberg; Kristiina Kuusniemi; Janne T Backman; Jouko Laitila; Kari Laine; Pertti J Neuvonen; Klaus T Olkkola; Teijo I Saari
Journal:  Eur J Clin Pharmacol       Date:  2016-08-10       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.